## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.2% below STRENGTH zone (4.0-10.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($339.06)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Does Stryker’s Premium Valuation Still Make Sense After Recent Share Price Volatility?**
- Source: Simply Wall Street | 20251206T160843 | Neutral | Relevance: 99%
-  Stryker (NYSE:SYK) has experienced recent share price volatility, with a 4.6% dip over the past year, though longer-term returns remain strong. Despite this, the company scores 0/6 on Simply Wall St's valuation checks, suggesting a premium. Discounted Cash Flow analysis indicates the stock might be 20.8% overvalued, while its P/E ratio of 47.3x is significantly higher than the industry average, signaling it is expensive even considering its growth prospects.

**2. Does Stryker’s Premium Valuation Still Make Sense After Recent Share Price Volatility?**
- Source: Simply Wall Street | 20251207T070919 | Neutral | Relevance: 98%
- Stryker's stock has experienced recent volatility but has shown strong longer-term returns, driven by its medical technology portfolio. Despite its strong performance, Simply Wall St's valuation checks, including Discounted Cash Flow and Price to Earnings ratio, suggest that the stock may be overvalued. The article introduces "Narratives" as a way for investors to connect their view of Stryker's business to its fair value.

**3. Cerity Partners LLC Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251207T093034 | Neutral | Relevance: 98%
-  Cerity Partners LLC has increased its stake in Stryker Corporation (NYSE:SYK) by 16.1% during the second quarter, now owning 314,580 shares valued at $124.47 million. This move is part of broader institutional investor activity, although some insiders have recently sold shares. Analyst ratings for Stryker are generally positive, with a "Moderate Buy" consensus.

**4. Amundi Has $423.53 Million Stock Holdings in Stryker Corporation $SYK**
- Source: MarketBeat | 20251206T080905 | Somewhat-Bullish | Relevance: 98%
-  Amundi significantly increased its stake in Stryker Corporation by 37.9% in Q2, bringing its total holdings to 1,080,958 shares valued at $423.53 million. Despite this, company insiders have been net sellers, with Director Ronda E. Stryker selling a large block of shares. Stryker (NYSE:SYK) recently reported strong quarterly earnings, surpassing estimates with $3.19 EPS and $6.06 billion in revenue, and provided optimistic guidance for FY2025.

**5. Stryker (SYK) Shows ‘Muscle’ at Investor Day, but Truist Stays Neutral**
- Source: Insider Monkey | 20251206T142900 | Somewhat-Bullish | Relevance: 98%
-  Stryker Corporation (NYSE: SYK) demonstrated its strength as a large-cap MedTech company at its Investor Day, leading Truist to boost its price target. Despite the positive outlook and strong Q3 2025 earnings, Truist maintained a neutral stance, preferring companies with faster earnings growth. Stryker continues to appeal to income investors with its 32-year dividend growth streak and commitment to margin expansion.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-14 | Truist Securiti | $400 | $392 | +2% |
| 2025-11-14 | Wells Fargo | $456 | $452 | +1% |
| 2025-11-14 | Needham | $448 | $448 | 0% |
| 2025-11-14 | BTIG | $410 | $410 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-14 | Truist Securiti | main | Hold |
| 2025-11-14 | Wells Fargo | main | Overweight |
| 2025-11-14 | Needham | reit | Buy |
| 2025-11-14 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($34.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.1% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $35M sold (6 transactions in 90 days).
3. Long-term trend broken: trading 6.2% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 23.7x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($34.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.2B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 23.7 |
| Current P/E | 26.1 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.2% to -5.2% (-4.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.2pp (needs >4.0% for momentum thesis). AM_20 at -3.3% indicates price below own 20MA trend. Below SMA200 (0.94x), long-term trend not supportive. MACD histogram bearish (-0.76), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.23% (CS: 13) | Weak |
| RSI_14 | 37.3 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 0.967x | Below |
| vs SMA50 | 0.961x | Below |
| vs SMA200 | 0.938x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $353.60
- **Stop Loss:** $339.06 (4.1% risk)
- **Target:** $368.14 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 34
- **Position Value:** $12,022.40
- **Portfolio %:** 12.02%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*